The abstract is read at the publisher; the summary is JClub's.
An intestine–liver–tumor multi-organoid system shows that liver activation/deactivation shifts anti-tumor drug effectiveness, revealing docetaxel and 5-FU decreases and capecitabine and ifosfamide increases.
- Why it matters: Single tumor organoid models miss physiologically relevant intestinal absorption and liver metabolism, limiting accurate efficacy and toxicity assessment for metabolism-dependent drugs.
- What they did: The authors built a multi-organoid platform that simulates in vivo absorption and metabolism using intestinal and liver organoids plus tumor organoids, including fluidic and gravity-driven multi-organ interactions.
- The result: In tumor organoids, liver-deactivated docetaxel and 5-FU show decreased effectiveness, while liver-activated capecitabine and ifosfamide show increased efficacy, effects not detectable with tumor organoids alone.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.